Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Suya Du; Yanjiao Li; Zhen Geng; Zhen Geng; Zhen Geng; Qi Zhang; Leo H. Buhler; Leo H. Buhler; Carmen Gonelle-Gispert; Yi Wang; Yi Wang; Yi Wang

doi:10.3389/fimmu.2022.869514

Frontiers in Immunology (Apr 2022)

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Suya Du,
Yanjiao Li,
Zhen Geng,
Zhen Geng,
Zhen Geng,
Qi Zhang,
Leo H. Buhler,
Leo H. Buhler,
Carmen Gonelle-Gispert,
Yi Wang,
Yi Wang,
Yi Wang

Affiliations

Suya Du: Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Yanjiao Li: School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Zhen Geng: Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu, China
Zhen Geng: Institute of Organ Transplantation, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Zhen Geng: Chinese Academy of Sciences, Sichuan Translational Medicine Research Hospital, Chengdu, China
Qi Zhang: School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Leo H. Buhler: Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu, China
Leo H. Buhler: Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Carmen Gonelle-Gispert: Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Yi Wang: Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu, China
Yi Wang: Institute of Organ Transplantation, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Yi Wang: Chinese Academy of Sciences, Sichuan Translational Medicine Research Hospital, Chengdu, China

DOI: https://doi.org/10.3389/fimmu.2022.869514
Journal volume & issue: Vol. 13

Abstract

Read online

Diabetes is a metabolic disease characterized by insulin deficiency. Bioengineering of stem cells with the aim to restore insulin production and glucose regulation has the potential to cure diabetic patients. In this review, we focus on the recent developments for bioengineering of induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and pancreatic progenitor cells in view of generating insulin producing and glucose regulating cells for β-cell replacement therapies. Recent clinical trials using islet cells derived from stem cells have been initiated for the transplantation into diabetic patients, with crucial bottlenecks of tumorigenesis, post-transplant survival, genetic instability, and immunogenicity that should be further optimized. As a new approach given high expectations, bioengineered islets from stem cells occupies considerable potential for the future clinical application and addressing the treatment dilemma of diabetes.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords